Inclusion bodies as potential vehicles for recombinant protein delivery into epithelial cells
© Liovic et al.; licensee BioMed Central Ltd. 2012
Received: 28 February 2012
Accepted: 14 May 2012
Published: 24 May 2012
We present the potential of inclusion bodies (IBs) as a protein delivery method for polymeric filamentous proteins. We used as cell factory a strain of E. coli, a conventional host organism, and keratin 14 (K14) as an example of a complex protein. Keratins build the intermediate filament cytoskeleton of all epithelial cells. In order to build filaments, monomeric K14 needs first to dimerize with its binding partner (keratin 5, K5), which is then followed by heterodimer assembly into filaments.
K14 IBs were electroporated into SW13 cells grown in culture together with a “reporter” plasmid containing EYFP labeled keratin 5 (K5) cDNA. As SW13 cells do not normally express keratins, and keratin filaments are built exclusively of keratin heterodimers (i.e. K5/K14), the short filamentous structures we obtained in this study can only be the result of: a) if both IBs and plasmid DNA are transfected simultaneously into the cell(s); b) once inside the cells, K14 protein is being released from IBs; c) released K14 is functional, able to form heterodimers with EYFP-K5.
Soluble IBs may be also developed for complex cytoskeletal proteins and used as nanoparticles for their delivery into epithelial cells.
KeywordsInclusion bodies E. coli Keratin Intermediate filaments Skin Therapy Electroporation
When expressing recombinant proteins in bacteria, one of the most common side effects is the formation of inclusion bodies (IBs) . Until recently IBs were thought of as blocks of misfolded and inactive proteins. As it was difficult and expensive to purify and refold recombinant proteins from such aggregates, a whole range of strategies was adopted to reduce or avoid IB formation. Surprisingly, although there was published evidence that inclusion bodies can also contain biologically active proteins [2, 3], it was not until recently that this phenomenon was fully acknowledged and further investigated [4, 5]. Many different protocols for IB production have been published, focusing on the various parameters that can affect IB quality such as the genetic background of the host organism, specific growth conditions and IB isolation [6–18]. Furthermore, the term “non-classical” inclusion bodies (ncIBs) was introduced to describe IBs containing a significant amount of properly folded protein, which in addition could be extracted under non-denaturing conditions. Although the major factor in obtaining soluble IBs is the target protein’s structure, the type of host organism used and the design of the biosynthesis process may also modulate IB size and degree of solubility. The fact that inclusion bodies may contain biologically active proteins has been already shown for a number of proteins, from GFP [4, 16, 17], to recombinant cytokines such as granulocyte colony-stimulating factor  and a number of enzymes [19–23]. Therefore, the development of IBs as a novel type of recombinant protein delivery machines has great potential with applications in medicine, and it has been also recently patented .
The aim of this study was to provide evidence that IBs may be also used as method of recombinant protein delivery for complex proteins. By using an already published protocol for IB production via the E. coli BL21 (DE3) strain , we obtained keratin 14 (K14) ncIBs of several hundred nanometres in size, which were subsequently introduced into SW13 epithelial cells grown in culture by means of electroporation. We show that inside the cells a portion of the K14 protein is released and dimerizes with EYFP labeled K5, resulting in short filamentous structures, precursors of keratin filaments.
Results and discussion
Overall, the results of these two experiments (Figure 3A with B) are similar, as in both experiments dot-like particles, larger speckles and short filamentous structures (see arrows) are visible. Importantly, although the K14 ncIBs used in these experiments were not purified in any particular way after extraction from bacterial cells, no cytotoxic effect was observed even at longer time points (7 days) after electroporation (data not shown).
We provide for the first time evidence that a polymeric cytoskeletal protein may be produced in the form of inclusion bodies and used in this form to supplement epithelial cells lacking it. The production is cost effective (cheap), no particular purification step is needed, as our ncIBs appear not to be cytotoxic, and with the end result similar to the effect of a plasmid DNA construct. In this study electroporation was chosen as method for K14 ncIB delivery because of their size (currently several hundred nanometers). During electroporation small hydrophilic pores are transiently formed in the cell membrane, and this method has been demonstrated to work well also in in vivo experiments [25–27], particularly on skin. Nevertheless, other approaches may work as well, especially in the case of delivery of smaller IBs, which is something that needs to be further investigated. A choice of a different E. coli strain as cell factory could help improve the biosynthesis process, however there have been also reports on the advantages of host organisms such as gram-positive bacteria (Bacillus sp.), yeast and fungi [28–30], which can circumvent some of the limitations of E. coli. In fact, the choice of a different host organism may be the next appropriate step towards the optimization of this particular ncIB synthesis protocol, as a significantly higher proportion of properly folded protein needs to be delivered in order to achieve a therapeutic effect. The data presented in this manuscript is extremely promising, as it indicates that soluble IBs may be also obtained for cellular proteins that exert their function by building intricate polymeric structures. As skin is the most accessible organ by far, this method may particularly find possible applications in dermatology and the cosmetics industry.
Material and methods
Cell culture, electroporation and microscopy
Human adrenal carcinoma cells (SW13 cell line) were grown in DMEM (PAA, Austria) supplemented with 10%FBS (PAA, Austria) and an antibiotic-antimicotic reagent (cat no 15240–062, Gibco), at 37°C and 5% CO2.
Cells were cultivated in T75 cm2 cell culture flasks until confluence. Before electroporation, cells were trypsinized and counted. In each electroporation experiment 5x106 cells were used.
IBs were resuspended in PBS buffer and an aliquot was subsequently diluted in electroporation buffer. Approximately 150 μg of K14 IBs and 10 μg of plasmid DNA (with EYFP-K5) was mixed and electroporated into SW13 cells using a Gene Pulser (Bio-Rad) electroporator set at 125 μF capacitance extender, 200 Ω pulse controler, 25 μF gene pulser capacitance and 1.5 kV voltage. In the positive control experiment 10 μg of each plasmid DNA (EYFP-K5 and EYFP-K14) were mixed and electroporated under the following Gene-Pulser settings: capacitance extender 125 μF, pulse controler 200 Ω, gene pulser capacitance 3 μF, voltage 2.5 kV. After electroporation cells were plated out onto 13 mm coverslips and incubated for a further 24 hrs, 48 hrs, 72 hrs and 7 days. At each time point cells were fixed with methanol-acetone (1:1), immunostained with a primary mouse monoclonal antibody against K14 (LL001) followed by a goat-anti-mouse FITC labeled secondary antibody (Alexa Fluor, Molecular Probes). Coverslips were analyzed on a Zeiss T200 inverted microscope operated by Zeiss Axiovision software and representative images were taken with a Zeiss Axiocam colour camera.
Keratin constructs and inclusion bodies production
Keratin 14 (KRT14) cDNA sequence was cloned into pET23b expression plasmid (Novagen) using the Nde I restriction site. A previously published protocol for IB production was used . In brief, the E. coli BL21 (DE3) strain (Novagen) was used. Inclusion bodies were produced in a shake culture flask with GYSP/amp100 medium, at 25°C and 160 rpm, until the culture reached the stationary phase. At this point bacterial cells were disrupted using a high-pressure homogenizer Emulsiflex-C5 (Avestin) at operating pressure 75–100 MPa. After cell disruption IBs were washed twice with PBS buffer and stored for further analysis and applications. The supernatant (soluble protein fraction) was also stored for analysis.
Keratin 5 cDNA sequence was cloned into the pEYFP-C1 plasmid (Clontech) using Eco RI and Bam HI restriction sites.
K14 protein extraction from IBs
IBs resuspended in solubilizing buffer (40 mM Tris/HCl with 0.2% N-lauroyl sarcosine, pH 8.0) were incubated in a shaker for 24 hrs at 20°C, then centrifuged at 4400 g for 15 minutes. N-lauroyl sarcosine was removed using a Dovex 1 x 4–50 ion exchange resin (Sigma).
In a parallel experiment IBs were also dissolved in DMEM after a 24 hrs incubation at 20°C in a shaker. The soluble and insoluble fractions were separated by centrifugation at 4400 g for 15 minutes. Samples were analyzed on 4-12% Nu-PAGE Bis-Tris SDS-PAGE gels (Invitrogen) and stained with Colloidal Blue (Invitrogen). Western blot detection was performed using a primary mouse monoclonal antibody against K14 (LL001) followed by a secondary HRP labeled anti-mouse secondary antibody (Sigma).
Scanning electron microscopy
IBs were thoroughly washed in pure water, mounted on gold-coated polycarbonate membrane filter with a 0.22 μm pore size (IsoporeTM, Millipore). Samples were analyzed using a high-resolution Zeiss SUPRA 35 VP field emission scanning electron microscope.
We thank the Slovenian Research Agency for funding our research through grants J3-2274-0381 and J3-3617-0381 to M. Liovic, and P1-0104 to R. Komel.
- Martinez-Alonso M, Gonzalez-Montalban N, Garcia-Fruitos E, Villaverde A: Learning about protein solubility from bacterial inclusion bodies. Microb Cell Fact 2009, 8: 4. 10.1186/1475-2859-8-4View ArticleGoogle Scholar
- Tokatlidis K, Dhurjati P, Millet J, Beguin P, Aubert JP: High activity of inclusion bodies formed in Escherichia coli overproducing Clostridium thermocellum endoglucanase D. FEBS Lett 1991, 282: 205-208. 10.1016/0014-5793(91)80478-LView ArticleGoogle Scholar
- Worrall DM, Goss NH: The formation of biologically active beta-galactosidase inclusion bodies in Escherichia coli. Aust J Biotechnol 1989, 3: 28-32.Google Scholar
- Garcia-Fruitos E, Gonzalez-Montalban N, Morell M, Vera A, Ferraz RM, Aris A, Ventura S, Villaverde A: Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. Microb Cell Fact 2005, 4: 27. 10.1186/1475-2859-4-27View ArticleGoogle Scholar
- Jevsevar S, Gaberc-Porekar V, Fonda I, Podobnik B, Grdadolnik J, Menart V: Production of nonclassical inclusion bodies from which correctly folded protein can be extracted. Biotechnol Prog 2005, 21: 632-639.View ArticleGoogle Scholar
- Vera A, Gonzalez-Montalban N, Aris A, Villaverde A: The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. Biotechnol Bioeng 2007, 96: 1101-1106. 10.1002/bit.21218View ArticleGoogle Scholar
- Garcia-Fruitos E, Aris A, Villaverde A: Localization of functional polypeptides in bacterial inclusion bodies. Appl Environ Microbiol 2007, 73: 289-294. 10.1128/AEM.01952-06View ArticleGoogle Scholar
- Garcia-Fruitos E, Martinez-Alonso M, Gonzalez-Montalban N, Valli M, Mattanovich D, Villaverde A: Divergent genetic control of protein solubility and conformational quality in Escherichia coli. J Mol Biol 2007, 374: 195-205. 10.1016/j.jmb.2007.09.004View ArticleGoogle Scholar
- Garcia-Fruitos E, Rodriguez-Carmona E, Diez-Gil C, Ferraz RM, Vazquez E, Corchero JL, Cano-Sarabia M, Ratera I, Ventosa N, Veciana J, Villaverde A: Surface Cell Growth Engineering Assisted by a Novel Bacterial Nanomaterial. Adv Mater 2009, 21: 4249. 10.1002/adma.200900283View ArticleGoogle Scholar
- Garcia-Fruitos E, Seras-Franzoso J, Vazquez E, Villaverde A: Tunable geometry of bacterial inclusion bodies as substrate materials for tissue engineering. Nanotechnology 2010, 21: 205101. 10.1088/0957-4484/21/20/205101View ArticleGoogle Scholar
- Díez-Gil C, Krabbenborg S, Garcia-Fruitos E, Vazquez E, Rodriguez-Carmona E, Ratera I, Ventosa N, Seras-Franzoso J, Cano-Garrido O, Ferrer-Miralles N, Villaverde A, Veciana J: The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. Biomaterials 2010, 31: 5805-5812. 10.1016/j.biomaterials.2010.04.008View ArticleGoogle Scholar
- Martinez-Alonso M, Garcia-Fruitos E, Villaverde A: Yield, solubility and conformational quality of soluble proteins are not simultaneously favored in recombinant Escherichia coli. Biotechnol Bioeng 2008, 101: 1353-1358. 10.1002/bit.21996View ArticleGoogle Scholar
- Martinez-Alonso M, Vera A, Villaverde A: Role of the chaperone DnaK in protein solubility and conformational quality in inclusion body-forming Escherichia coli cells. FEMS Microbiol Lett 2007, 273: 187-195. 10.1111/j.1574-6968.2007.00788.xView ArticleGoogle Scholar
- de Groot NS, Ventura S: Protein activity in bacterial inclusion bodies correlates with predicted aggregation rates. J Biotechnol 2006, 125: 110-113. 10.1016/j.jbiotec.2006.02.026View ArticleGoogle Scholar
- de Groot NS, Ventura S: Effect of temperature on protein quality in bacterial inclusion bodies. FEBS Lett 2006, 580: 6471-6476. 10.1016/j.febslet.2006.10.071View ArticleGoogle Scholar
- Peternel S, Gaberc-Porekar V, Komel R: Bacterial Growth Conditions Affect Quality of GFP Expressed Inside Inclusion Bodies. Acta Chim Slov 2009, 56: 860-867.Google Scholar
- Peternel S, Grdadolnik J, Gaberc-Porekar V, Komel R: Engineering inclusion bodies for non-denaturing extraction of functional proteins. Microb Cell Fact 2008, 7: 34. 10.1186/1475-2859-7-34View ArticleGoogle Scholar
- Peternel S, Liovic M: Production of Recombinant Proteins in Bacteria: The Inclusion Bodies Formation and their Use in Biomedicine. Recent Patents on Biomedical Engineering 2010, 3: 153-161.View ArticleGoogle Scholar
- Nahalka J, Gemeiner P, Bucko M, Wang PG: Bioenergy beads: a tool for regeneration of ATP/NTP in biocatalytic synthesis. Artif Cells Blood Substit Immobil Biotechnol 2006, 34: 515-521. 10.1080/10731190600862886View ArticleGoogle Scholar
- Nahalka J, Nidetzky B: Fusion to a pull-down domain: a novel approach of producing Trigonopsis variabilis D-amino acid oxidase as insoluble enzyme aggregates. Biotechnol Bioeng 2007, 97: 454-461. 10.1002/bit.21244View ArticleGoogle Scholar
- Nahalka J, Vikartovska A, Hrabarova E: A crosslinked inclusion body process for sialic acid synthesis. J Biotechnol 2008, 134: 146-153. 10.1016/j.jbiotec.2008.01.014View ArticleGoogle Scholar
- Nahalka J, Patoprsty V: Enzymatic synthesis of sialylation substrates powered by a novel polyphosphate kinase (PPK3). Org Biomol Chem 2009, 7: 1778-1780. 10.1039/b822549bView ArticleGoogle Scholar
- Nahalka J: Physiological aggregation of maltodextrin phosphorylase from Pyrococcus furiosus and its application in a process of batch starch degradation to alpha-D-glucose-1-phosphate. J Ind Microbiol Biotechnol 2008, 35: 219-223. 10.1007/s10295-007-0287-4View ArticleGoogle Scholar
- Vázquez E, Corchero JL, Burgueño JF, Seras-Franzoso J, Kosoy A, Bosser R, Mendoza R, Martínez-Láinez JM, Rinas U, Fernández E, Ruiz-Avila L, García-Fruitós E, Villaverde A: Functional inclusion bodies produced in bacteria as naturally occurring nanopills for advanced cell therapies. Adv Mater 2012, 24: 1742-1747. 10.1002/adma.201104330View ArticleGoogle Scholar
- Prausnitz MR, Bose VG, Langer R, Weaver JC: Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci USA 1993, 90: 10504-10508. 10.1073/pnas.90.22.10504View ArticleGoogle Scholar
- Chizmadzhev YA, Indenbom AV, Kuzmin PI, Galichenko SV, Weaver JC, Potts RO: Electrical properties of skin at moderate voltages: contribution of appendageal macropores. Biophys J 1998,74(2 Pt 1):843-856.View ArticleGoogle Scholar
- Ilic L, Gowrishankar TR, Vaughan TE, Herndon TO, Weaver JC: Microfabrication of individual 200 microm diameter transdermal microconduits using high voltage pulsing in salicylic acid and benzoic acid. J Invest Dermatol 2001, 116: 40-49. 10.1046/j.1523-1747.2001.00214.xView ArticleGoogle Scholar
- Zweers JC, Barák I, Becher D, Driessen AJ, Hecker M, Kontinen VP, Saller MJ, Vavrová L, van Dijl JM: Towards the development of Bacillus subtilis as a cell factory for membrane proteins and protein complexes. Microb Cell Fact 2008, 7: 10. 10.1186/1475-2859-7-10View ArticleGoogle Scholar
- Joosten V, Lokman C, Hondel CA, Punt PJ: The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microb Cell Fact 2003, 2: 1. 10.1186/1475-2859-2-1View ArticleGoogle Scholar
- Nakashima N, Mitani Y, Tamura T: Actinomycetes as host cells for production of recombinant proteins. Microb Cell Fact 2005, 4: 7. 10.1186/1475-2859-4-7View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.